Retatrutide Phase 2 trial (NCT04881760)
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 338
- actual
- Start
- 20 May 2021 (actual)
- Primary completion
- 16 May 2022 (actual)
- Sponsor
- Eli Lilly and Company
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Placebo | Placebo comparator | Drug: Placebo | Participants received placebo matched to LY3437943 administered as subcutaneous (SC) injection once-weekly (QW). |
| 1 milligram (mg) LY3437943 | Experimental | Drug: LY3437943 | Participants received 1 mg LY3437943 administered as SC injection QW. |
| 4 mg LY3437943 (2 mg) | Experimental | Drug: LY3437943 | Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW. |
| 4 mg LY3437943 | Experimental | Drug: LY3437943 | Participants received 4 mg LY3437943 administered as SC injection QW. |
| 8 mg LY3437943 (2 mg) | Experimental | Drug: LY3437943 | Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW. |
| 8 mg LY3437943 (4 mg) | Experimental | Drug: LY3437943 | Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW. |
| 12 mg LY3437943 (2 mg) | Experimental | Drug: LY3437943 | Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW. |
Primary endpoint
| Measure | Time frame |
|---|---|
| Mean Percent Change From Baseline in Body Weight | Baseline, Week 24 |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Mean Percent Change From Baseline in Body Weight | Baseline, Week 48 |
| Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction | Week 24 |
| Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction | Week 48 |
| Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction | Week 24 |
| Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction | Week 48 |
| Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction | Week 24 |
| Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction | Week 48 |
| Mean Change From Baseline in Body Weight | Baseline, Week 24 |
| Mean Change From Baseline in Body Weight | Baseline, Week 48 |
| Mean Change From Baseline in BMI | Baseline, Week 24 |
| Mean Change From Baseline in BMI | Baseline, Week 48 |
| Mean Change From Baseline in Waist Circumference | Baseline, Week 24 |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Results
Results are posted on the registry. Open the ClinicalTrials.gov record for NCT04881760.
The obesity phase 2 trial of retatrutide in the New England Journal of Medicine
Participants were randomised 2:1:1:1:1:2:2 to weekly retatrutide from 1 mg to 12 mg, with 4 mg and 8 mg arms split by a 2 mg or 4 mg starting dose, or placebo for 48 weeks.[2]
At 48 weeks weight changed by -8.7% on 1 mg, -17.1% on combined 4 mg, -22.8% on combined 8 mg and -24.2% on 12 mg, against -2.1% on placebo.[2]
Gastrointestinal events were dose-related and partially mitigated by a lower starting dose of 2 mg rather than 4 mg.[2]
Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter.[2]
The liver fat substudy
Mean relative change in liver fat at 24 weeks was -42.9% (1 mg), -57.0% (4 mg), -81.4% (8 mg), -82.4% (12 mg) and +0.3% on placebo.[3]
Normal liver fat (under 5%) was reached by 27%, 52%, 79% and 86% of participants across the four retatrutide doses, and 0% on placebo.[3]
Sources
- 1A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related ComorbiditiesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
- 2Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine · 2023PMID 37366315Accessed 2 Oct 2026
- 3Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.Nature medicine · 2024PMID 38858523Accessed 2 Oct 2026
Found an error? Report a correction.